Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : E7386
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : E7386 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2022
Lead Product(s) : E7386
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E7386,Lenvatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Prism Biolab
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : E7386 is a CBP/β-catenin inhibitor that inhibits CBP and β-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression is expected to suppress tumor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : E7386,Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Prism Biolab
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E7386
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : E7386 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : E7386
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E7386
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : E7386 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : E7386
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable